Integra LifeSciences (NASDAQ:IART) Trading Down 4.3% – Time to Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART)’s stock price dropped 4.3% on Wednesday . The stock traded as low as $22.71 and last traded at $22.92. Approximately 50,096 shares traded hands during trading, a decline of 92% from the average daily volume of 656,643 shares. The stock had previously closed at $23.95.

Analysts Set New Price Targets

Separately, Morgan Stanley started coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target for the company. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences presently has an average rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Trading Up 0.1 %

The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -247.42, a price-to-earnings-growth ratio of 0.73 and a beta of 1.23. The company has a fifty day moving average price of $23.81 and a 200-day moving average price of $21.94. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 earnings per share. On average, equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership raised its stake in shares of Integra LifeSciences by 7.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after acquiring an additional 913 shares in the last quarter. KBC Group NV grew its holdings in Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares during the last quarter. Quadrant Capital Group LLC raised its position in shares of Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 1,371 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Integra LifeSciences by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company’s stock worth $872,000 after buying an additional 1,437 shares during the last quarter. Finally, Sterling Capital Management LLC grew its stake in Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after buying an additional 1,931 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.